001     126683
005     20240228140841.0
024 7 _ |a 10.1096/fj.14-267633
|2 doi
024 7 _ |a pmid:25857554
|2 pmid
024 7 _ |a 0892-6638
|2 ISSN
024 7 _ |a 1530-6860
|2 ISSN
024 7 _ |a altmetric:17898796
|2 altmetric
037 _ _ |a DKFZ-2017-02711
041 _ _ |a eng
082 _ _ |a 570
100 1 _ |a Heiss, Maximilian
|b 0
245 _ _ |a Endothelial cell spheroids as a versatile tool to study angiogenesis in vitro.
260 _ _ |a Bethesda, Md.
|c 2015
|b FASEB
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1507891992_19991
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Given the need for robust and cost-efficient in vitro models to study angiogenesis and reproducibly analyze potential pro- and antiangiogenic compounds in preclinical studies, we developed a 3-dimensional in vitro angiogenesis assay that is based on collagen gel-embedded, size-defined spheroids generated from cultured human umbilical vein endothelial cells (HUVECs). Despite its wide distribution, limitations, sensitivity, robustness, and improvements, the capacity of this assay for functional screening purposes has not been elucidated thus far. By using time-lapse video microscopy, we show that tip cells lead the formation of capillary-like and partially lumenized sprouts originating from the spheroids. Angiogenic sprouting from spheroids generated from 5 different primary cultured human endothelial cell types was induced by physiologic concentrations of vascular endothelial cell growth factor 165. Based on this assay system, we determined the capacity of 880 approved drugs to interfere with or boost angiogenic sprouting, thereby assessing their putative angiogenesis-related side effects or novel applications. However, although this assay allowed for a rapid and reproducible determination of functional IC50 values of individual compounds, the sprouting results were partially affected by the HUVEC passage number and donor variability. To overcome this limitation, immortalized HUVECs (iHUVECs) showing a more homogenous response in terms of proliferation and sprouting over multiple population doublings were used in the course of this study. Collectively, the spheroid-based angiogenesis assay provides a sensitive and versatile tool to study the impact of pro- and antiangiogenic determinants on multiple steps of the angiogenic cascade. It is compatible with different endothelial cell types and allows use of iHUVECs to improve its overall robustness.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Angiogenesis Inducing Agents
|2 NLM Chemicals
650 _ 7 |a Angiogenesis Inhibitors
|2 NLM Chemicals
650 _ 7 |a Indoles
|2 NLM Chemicals
650 _ 7 |a Pyrroles
|2 NLM Chemicals
650 _ 7 |a Recombinant Proteins
|2 NLM Chemicals
650 _ 7 |a SU 5402
|2 NLM Chemicals
650 _ 7 |a SU 5614
|2 NLM Chemicals
650 _ 7 |a VEGFA protein, human
|2 NLM Chemicals
650 _ 7 |a Vascular Endothelial Growth Factor A
|2 NLM Chemicals
650 _ 7 |a Fibroblast Growth Factor 2
|0 103107-01-3
|2 NLM Chemicals
700 1 _ |a Hellström, Mats
|b 1
700 1 _ |a Kalén, Mattias
|b 2
700 1 _ |a May, Tobias
|b 3
700 1 _ |a Weber, Holger
|b 4
700 1 _ |a Hecker, Markus
|b 5
700 1 _ |a Augustin, Hellmut
|0 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
|b 6
|u dkfz
700 1 _ |a Korff, Thomas
|b 7
773 _ _ |a 10.1096/fj.14-267633
|g Vol. 29, no. 7, p. 3076 - 3084
|0 PERI:(DE-600)1468876-1
|n 7
|p 3076 - 3084
|t The @FASEB journal
|v 29
|y 2015
|x 1530-6860
909 C O |o oai:inrepo02.dkfz.de:126683
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FASEB J : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FASEB J : 2015
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l Vaskuläre Onkologie und Metastasierung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21